Eli Lilly & Co. (LLY), whose top-selling antipsychotic drug Zyprexa faces generic competition in October, said it may bid for veterinary products being sold by Pfizer Inc. (PFE). Lilly, which had $1.39 billion in sales from animal-health products last year, is monitoring Pfizer’s plans to divest its unit, Chief Financial Officer Derica Rice said in a conference call with investors today. The Indianapolis-based drugmaker will pursue any assets it deems of interest, Rice said.
